Cargando…

Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report

BACKGROUND: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line chemotherapy for advanced MM is a combination with cisplatin and pemetrexed. However, nedapl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Mindan, Li, Zhixuan, Cai, Junfu, Zhong, Xianyang, Zheng, Wenchuan, Wu, Shuhan, Lin, Maohuang, Zhang, Qichuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628414/
https://www.ncbi.nlm.nih.gov/pubmed/37942039
http://dx.doi.org/10.21037/acr-22-102
_version_ 1785131752666169344
author Wu, Mindan
Li, Zhixuan
Cai, Junfu
Zhong, Xianyang
Zheng, Wenchuan
Wu, Shuhan
Lin, Maohuang
Zhang, Qichuan
author_facet Wu, Mindan
Li, Zhixuan
Cai, Junfu
Zhong, Xianyang
Zheng, Wenchuan
Wu, Shuhan
Lin, Maohuang
Zhang, Qichuan
author_sort Wu, Mindan
collection PubMed
description BACKGROUND: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line chemotherapy for advanced MM is a combination with cisplatin and pemetrexed. However, nedaplatin, a second-generation platinum-based antitumor agent, has the similar therapeutic effects as cisplatin but lower toxicity and higher water solubility. To our knowledge, this is the first case of co-existing pericardial and pleural MM treated with nedaplatin and pemetrexed and responding well. CASE DESCRIPTION: A 33-year-old woman, who had worked in a kiln for more than 10 years, suffered from dyspnea and chest tightness for 6 days. Chest computed tomography (CT) showed a massive pericardial effusion. She was diagnosed tuberculous pericarditis and received 6 months antituberculosis treatment (rifampicin, isoniazide, pyrazinamide, ethambutol). But it was ineffective and she was re hospitalized again due to massive pleural effusion and pericardial effusion. She was diagnosed with co-existing pericardial and pleural MM finally based on pleural biopsy and cytology of pericardial effusion. She was responding well excitedly to chemotherapy with nedaplatin and pemetrexed with high tolerance. Bone marrow toxicity or recurrent massive pericardial or pleural effusion were not observed during chemotherapy. However, she gave up chemotherapy and has survived for 22 months, from the onset symptoms. CONCLUSIONS: In terms of clinical tolerance and less adverse reactions, we suggest that chemotherapy of nedaplatin with pemetrexed may be a more appropriate treatment in advanced MM. Further clinical trials are warrant.
format Online
Article
Text
id pubmed-10628414
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-106284142023-11-08 Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report Wu, Mindan Li, Zhixuan Cai, Junfu Zhong, Xianyang Zheng, Wenchuan Wu, Shuhan Lin, Maohuang Zhang, Qichuan AME Case Rep Case Report BACKGROUND: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line chemotherapy for advanced MM is a combination with cisplatin and pemetrexed. However, nedaplatin, a second-generation platinum-based antitumor agent, has the similar therapeutic effects as cisplatin but lower toxicity and higher water solubility. To our knowledge, this is the first case of co-existing pericardial and pleural MM treated with nedaplatin and pemetrexed and responding well. CASE DESCRIPTION: A 33-year-old woman, who had worked in a kiln for more than 10 years, suffered from dyspnea and chest tightness for 6 days. Chest computed tomography (CT) showed a massive pericardial effusion. She was diagnosed tuberculous pericarditis and received 6 months antituberculosis treatment (rifampicin, isoniazide, pyrazinamide, ethambutol). But it was ineffective and she was re hospitalized again due to massive pleural effusion and pericardial effusion. She was diagnosed with co-existing pericardial and pleural MM finally based on pleural biopsy and cytology of pericardial effusion. She was responding well excitedly to chemotherapy with nedaplatin and pemetrexed with high tolerance. Bone marrow toxicity or recurrent massive pericardial or pleural effusion were not observed during chemotherapy. However, she gave up chemotherapy and has survived for 22 months, from the onset symptoms. CONCLUSIONS: In terms of clinical tolerance and less adverse reactions, we suggest that chemotherapy of nedaplatin with pemetrexed may be a more appropriate treatment in advanced MM. Further clinical trials are warrant. AME Publishing Company 2023-08-03 /pmc/articles/PMC10628414/ /pubmed/37942039 http://dx.doi.org/10.21037/acr-22-102 Text en 2023 AME Case Reports. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Case Report
Wu, Mindan
Li, Zhixuan
Cai, Junfu
Zhong, Xianyang
Zheng, Wenchuan
Wu, Shuhan
Lin, Maohuang
Zhang, Qichuan
Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title_full Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title_fullStr Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title_full_unstemmed Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title_short Co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
title_sort co-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628414/
https://www.ncbi.nlm.nih.gov/pubmed/37942039
http://dx.doi.org/10.21037/acr-22-102
work_keys_str_mv AT wumindan coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT lizhixuan coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT caijunfu coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT zhongxianyang coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT zhengwenchuan coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT wushuhan coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT linmaohuang coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport
AT zhangqichuan coexistingpericardialandpleuralmalignantmesotheliomarespondingwelltonedaplatinandpemetrexedacasereport